PCM
TNYA icon

Prelude Capital Management’s Tenaya Therapeutics TNYA Stock Holding History

Prelude Capital Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,059
Closed -$71.4K – 1351
2023
Q1 		$71.4K Buy
25,059
+14,600
+140% +$41K ﹤0.01% 982
2022
Q4 		$21K Buy
+10,459
New +$25.5K ﹤0.01% 1175

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Prelude Capital Management's TNYA Position: Q2 2023 in Review

Prelude Capital Management sold out of Tenaya Therapeutics (TNYA) in Q2 2023, closing a stake of 25,059 shares — an estimated $71.4K sold.

Prelude Capital Management first reported a position in TNYA in Q4 2022 and held it in 2 quarters. The position peaked at $71.4K in Q1 2023. 79 funds tracked by Wall St. Rank hold TNYA as of Q2 2023.

  • Prelude Capital Management reported no remaining Tenaya Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Prelude Capital Management sold 25,059 Tenaya Therapeutics shares in Q2 2023, an estimated $71.4K.
  • Prelude Capital Management first reported a position in Tenaya Therapeutics in Q4 2022 and held it in 2 quarters.
  • Prelude Capital Management's Tenaya Therapeutics position peaked at $71.4K in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.